Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Dupixent® (dupilumab) – New indication
September 28, 2022 - Sanofi and Regeneron announced the FDA approval of Dupixent (dupilumab), for the treatment of adult patients with prurigo nodularis.
